Cargando…

A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction

AIMS: We investigated the effects of CD34(+) cell therapy in patients with heart failure with preserved ejection fraction (HFpEF). METHODS AND RESULTS: In a prospective pilot study, we enrolled 30 patients with HFpEF. In Phase 1, patients were treated with medical therapy for 6 months. Thereafter, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vrtovec, Bojan, Frljak, Sabina, Poglajen, Gregor, Zemljic, Gregor, Cerar, Andraz, Sever, Matjaz, Haddad, Francois, Wu, Joseph C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	Cell Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540623/ https://www.ncbi.nlm.nih.gov/pubmed/35775390 http://dx.doi.org/10.1002/ejhf.2596

Ejemplares similares

Cell Therapy in Heart Failure with Preserved Ejection Fraction
por: Frljak, Sabina, et al.
Publicado: (2022)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
por: Poglajen, Gregor, et al.
Publicado: (2020)

Transendocardial CD34(+) Cell Transplantation in Noncompaction Cardiomyopathy: First-in-Man Case Study
por: Cerar, Andraz, et al.
Publicado: (2018)

Transendocardial CD34+ Cell Therapy does not Increase the Risk of Ventricular Arrhythmias in Patients with Chronic Heart Failure
por: Poglajen, Gregor, et al.
Publicado: (2019)

CD34(+) Cell Transplantation Improves Right Ventricular Function in Patients with Nonischemic Dilated Cardiomyopathy
por: Frljak, Sabina, et al.
Publicado: (2018)

Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure
por: Poglajen, Gregor, et al.
Publicado: (2019)

Stem Cell Therapy in Patients with Chronic Nonischemic Heart Failure
por: Poglajen, Gregor, et al.
Publicado: (2018)

Effects of Transendocardial CD34(+) Cell Transplantation on Diastolic Parameters in Patients with Nonischemic Dilated Cardiomyopathy
por: Bervar, Mojca, et al.
Publicado: (2017)

Impairment of myocardial perfusion correlates with heart failure severity in patients with non‐compaction cardiomyopathy
por: Cerar, Andraz, et al.
Publicado: (2020)

Transendocardial CD34(+) Cell Therapy Improves Local Mechanical Dyssynchrony in Patients With Nonischemic Dilated Cardiomyopathy
por: Žorž, Neža, et al.
Publicado: (2022)

Response to the letter to the editor: unravel the genetic background of noncompaction before relating it with myocardial hypoperfusion
por: Cerar, Andraz, et al.
Publicado: (2020)

(651) Long-Term Safety and Efficacy of Mrna Sars-Cov2 Vaccination in Heart Transplant Recipients
por: Poglajen, G., et al.
Publicado: (2023)

Outcomes of COVID-19 in Heart Transplant Recipients
por: Poglajen, G., et al.
Publicado: (2022)

Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly
por: Milinković, Ivan, et al.
Publicado: (2022)

Contemporary Challenges of Regenerative Therapy in Patients with Ischemic and Non-Ischemic Heart Failure
por: Banovic, Marko, et al.
Publicado: (2022)

Efficacy and Safety of mRNA SARS-CoV2 Vaccination in Heart Transplant Recipients
por: Poglajen, G., et al.
Publicado: (2022)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
por: Agarwalla, Anjali, et al.
Publicado: (2022)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

TNF-α Predicts Endothelial Function and Number of CD34(+) Cells after Stimulation with G-CSF in Patients with Advanced Heart Failure
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Endocrine disorders after heart transplantation: national cohort study
por: Rakusa, Matej, et al.
Publicado: (2020)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
por: Anker, Stefan D., et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction and the Role of Percentage of Delayed Enhancement Measured by Cardiac Magnetic Resonance in Predicting Therapeutic Response: A Multicentre Study
por: Nugara, Cinzia, et al.
Publicado: (2023)

High Intensity Exercises in Heart Failure with Preserved Ejection Fraction
por: Herdy, Artur Haddad, et al.
Publicado: (2018)

The Optimization of Short-Term Hepatocyte Preservation Before Transplantation
por: Fukuoka, Kengo, et al.
Publicado: (2017)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
por: Teerlink, John R., et al.
Publicado: (2020)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Global longitudinal strain is superior to ejection fraction for long‐term follow‐up after allogeneic hematopoietic stem cell transplantation
por: Watanabe, Marika, et al.
Publicado: (2022)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction
por: Ali, Danish, et al.
Publicado: (2023)

Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction
por: Zordoky, Beshay N., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h3p9363cl07hkcsaep1c0p003f